Current treatments for juvenile idiopathic arthritis

Joint Bone Spine

Volumn 77, Issue 6, 2010, Pages 511-516

  Quartier, Pierre ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adolescents; Biotherapies; Interleukins; Juvenile arthritis; Pediatrics

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; ETANERCEPT; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THALIDOMIDE; TOCILIZUMAB;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PSORIASIS; SHORT SURVEY; SIDE EFFECT; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UVEITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS;

EID: 78649928306     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.09.002     Document Type: Short Survey

References (58)

1. Petty R.E., Southwood T.R., Manners P., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
2. Angeles-Han S., Prahalad S. The genetics of juvenile idiopathic arthritis: what is new in 2010?. Curr Rheumatol Rep 2010, 12:87-93.
3. Hofer M., Mouy R., Prieur A.M. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 2001, 28:927-928.
4. Minden K Epidemiologie. Pädiatrische Rheumatologie 2007, Springer Medizin Verlag, Heidelberg, p. 179-181.
5. Ravelli A., Felici E., Magni-Manzoni S., et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005, 52:826-832.
6. Thorne J.E., Woreta F.A., Dunn J.P., et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010, 11:1436-1441.
7. Marvillet I., Terrada C., Quartier P., et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009, 76:383-388.
8. Giannini E.H., Ruperto N., Ravelli A., et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
9. Pouchot J., Larbre J.P., Lemelle I., et al. Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis. Joint Bone Spine 2002, 69:468-481.
10. Damasio M.B., Malattia C., Martini A., et al. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol 2010, 40:985-998.
11. Magni-Manzoni S., Ruperto N., Pistorio A., et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008, 59:1120-1127.
12. Wallace C.A., Ruperto N., Giannini E., et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290-2294.
13. Bader-Meunier B., Wouters C., Job-Deslandre C., et al. Recommandations pour la prise en charge des formes oligoarticulaire et polyarticulaires (en dehors de la polyarthrite rhumatoïde) d'arthrite juvénile idiopathique. Arch Pediatr 2010, 17:1085-1089.
14. Woo P., Southwood T.R., Prieur A.M., et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000, 43:1849-1857.
15. Albers H.M., Wessels J.A., van der Straaten R.J., et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009, 61:46-51.
16. Becker M.L., Rosé C.D., Cron R.Q., et al. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010, 37:870-875.
17. Tuková J., Chládek J., Nemcová D., et al. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009, 27:1047-1053.
18. Tuková J, Chládek J, Hroch M, et al. 677TT Genotype is associated with elevated risk of methotrexate (mtx) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 2010;37:2180-6.
19. Bartoli M., Tarò M., Magni-Manzoni S., et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:370-374.
20. Foell D., Wulffraat N., Wedderburn L.R., et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010 2010, 303(1266-73). [Erratum in: JAMA 2010;303:2034].
21. Heiligenhaus A., Mingels A., Heinz C., et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007, 17:743-748.
22. Silverman E., Mouy R., Spiegel L., et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005, 352:1655-1666.
23. Bader-Meunier B, Wouters C, Job-Deslandre C, et al. Recommandations pour la prise en charge de la forme systémique l'arthrite juvénile idiopathique (maladie de Still). Arch Pediatr 2010;17:1090-4.
24. Lehman T.J., Schechter S.J., Sundel R.P., et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004, 145:856-857.
25. De Kleer I.M., Brinkman D.M., Ferster A., et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004, 63:1318-1326.
26. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
27. Quartier P., Taupin P., Bourdeaut F., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093-1101.
28. Horneff G., Schmeling H., Biedermann T., et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1638-1644.
29. Ruperto N., Lovell D.J., Cuttica R., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007, 56:3096-3106.
30. Lovell D.J., Ruperto N., Goodman S., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359:810-820.
31. Ruperto N., Lovell D.J., Quartier P., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372:383-391.
32. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
33. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2183-4.
34. Tzaribachev N., Kuemmerle-Deschner J., Eichner M., et al. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int 2008, 10:1031-1034.
35. Horneff G., De Bock F., Foeldvari I., et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009, 68:519-525.
36. Prince F.H., Twilt M., ten Cate R., et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009, 68:635-641.
37. Lovell D.J., Reiff A., Ilowite N.T., et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008, 58:1496-1504.
38. Giannini E.H., Ilowite N.T., Lovell D.J., et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2794-2804.
39. Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010;49:1694-8.
40. Tynjälä P., Kotaniemi K., Lindahl P., et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008, 47:339-344.
41. Ruperto N., Lovell D.J., Cuttica R., et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010, 69:718-722.
42. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
43. Lequerré T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302-308.
44. Gattorno M., Piccini A., Lasigliè D., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:1505-1515.
45. Zeft A., Hollister R., LaFleur B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009, 15:161-164.
46. Ilowite N., Porras O., Reiff A., et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009, 28:129-137.
47. Dinarello C.A. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009, 360:2467-2470.
48. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol 2009, 21:533-537.
49. De Benedetti F, et al. EULAR 2010, Roma. OP0273. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (SJIA); 12-week data from the phase 3 Tender trial.
50. Imagawa T., et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset. Ann Rheum Dis 2007, 66(Suppl. II):550.
51. Zulian F., Balzarin M., Falcini F., et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 2010, 62:821-825.
52. Billiau A.D., Loop M., Le P.Q., et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 2010, 49:1550-1558.
53. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010 Jul 28 [Epub ahead of print].
54. Simon D., Bechtold S. Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis. Horm Res 2009, 72(Suppl. 1):55-59.
55. Simon D. Safety of growth hormone treatment in children with juvenile idiopathic arthritis. Horm Res 2009, 72(Suppl. 1):65-68.
56. Bechtold S., Dalla Pozza R., Schwarz H.P., et al. Effects of growth hormone treatment in juvenile idiopathic arthritis: bone and body composition. Horm Res 2009, 72(Suppl. 1):60-64.
57. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2010 Jul 1 [Epub ahead of print].
58. Stinson JN, McGrath PJ, Hodnett ED, et al. An Internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. J Rheumatol 2010;37:1944-52.